Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 39

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
53 664 925 1,560 Total cost of biopharmaceutical and other revenue1,091 3,112 7,361 9,762 Intangible asset amortization - cost of revenue2,707 2,917 7,959 8,741 Gross profit91,282 79,010 260,559 219,391 Operating expenses:Research and development:Compensation expense9,028 8,906 27,840 26,356 Direct research and development expense3,512 5,479 10,946 14,596 Other research and development expenses (4)1,586 1,338 5,278 4,195 Allocation of facilities and IT expenses1,855 1,851 5,901 4,857 Total research and development15,981 17,574 49,965 50,004 Selling and marketing:Compensation expense16,977 15,814 52,214 50,517 Direct marketing expense1,376 1,427 3,564 4,613 Other selling and marketing expenses (5)3,332 3,271 10,880 9,897 Allocation of facilities and IT expenses2,770 2,100 7,567 5,583 Total selling and marketing24,455 22,612 74,225 70,610 General and administrative:Compensation expense20,688 18,958 62,121 59,824 Other general and administrative expenses (6)14,508 14,565 56,132 45,048 Allocation of facilities and IT expenses(7,918)(7,781)(24,836)(21,175)Total general and administrative27,278 25,742 93,417 83,697 Impairment of assets— 185 20,505 614 Intangible asset amortization - operating expenses622 880 1,865 2,499 Other income, net4,057 (4,831)(6,985)(10,334)Income tax (benefit) provision(248)1,693 2,363 3,276 Net income$19,137 $15,155 $25,204 $19,025 

20

________________(1)Other cost of testing revenue includes cytopathology services, depreciation